Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2006 Jul;62(1):27-34.
doi: 10.1111/j.1365-2125.2006.02714.x.

Recent developments in the clinical pharmacology of classical cytotoxic chemotherapy

Alan V Boddy  1
Affiliations
Review

Recent developments in the clinical pharmacology of classical cytotoxic chemotherapy

Alan V Boddy. Br J Clin Pharmacol. 2006 Jul.

Abstract

Advances in analytical methods, imaging techniques and an increased understanding of the influence of pharmacogenetic factors have added to our knowledge of the pharmacology of many chemotherapeutic agents. Extending the use of these approaches to pharmacodynamic end-points, together with the application of population-based modelling techniques, offers the potential to develop truly individualized therapy in the future.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Calvert AH, Newell DR, Gumbrell LA, O'Reilly S, Burnell M, Boxall FE, Siddik ZH, Judson IR, Gore ME, Wiltshaw E. Carboplatin dosage: prospective evaluation of a simple formula based on renal function. J Clin Oncol. 1989;7:1748–56. - PubMed
    1. Jodrell DI, Egorin MJ, Canetta RM, Langenberg P, Goldbloom EP, Burroughs JN, Goodlow JL, Tan S, Wiltshaw E. Relationships between carboplatin exposure and tumor response and toxicity in patients with ovarian cancer. J Clin Oncol. 1992;10:520–8. - PubMed
    1. Evans WE, Relling MV, Rodman JH, Crom WR, Boyett JM, Ching-Hon P. Conventional compared with individualised chemotherapy for childhood acute lymphoblastic leukemia. N Engl J Med. 1998;338:499–505. - PubMed
    1. Joel SP, Ellis P, O'Byrne K, Papamichael D, Hall M, Penson R, Nicholls S, O'Donnell C, Constantinou A, Woodhull J, Nicholson M, Smith I, Talbot D, Slevin M. Therapeutic monitoring of continuous infusion etoposide in small-cell lung cancer. J Clin Oncol. 1996;14:1903–12. - PubMed
    1. Cobleigh MA, Bogel CL, Tripathy D, Tobert NJ, Scholl S, Fehrenbacher L, Wolter JM, Paton V, Shak S, Lieberman G, Slamon DJ. Mulitnational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after cheotherapy for metastatic disease. J Clin Oncol. 1999;17:2639–48. - PubMed

Substances